Loading...
OTCM
VDRM
Market cap493kUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-84.00%
IPO
-100.00%
Name

Viaderma Inc

Chart & Performance

D1W1MN
OTCM:VDRM chart
P/E
120.45
P/S
0.82
EPS
0.00
Div Yield, %
Shrs. gr., 5y
22.58%
Rev. gr., 5y
67.19%
Revenues
600k
+11.07%
17,95815,90425,262,56226,828,83319,007,639191,777251,98144,69145,97310,39511,468514,007540,648600,498
Net income
4k
-99.31%
-141,484-19,0844,094,6234,506,9262,672,78527,121-121,806-1,518,384-2,998,022-599,270-431,673-994,178590,6744,097
CFO
0k
P
-21,6641,6913,308,0437,777,0546,054,149-11,189-12,064-167,361-83,901-15,116-8,7691,425-1,4920

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.
IPO date
Jun 10, 2008
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT